Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics

References

• TandonRAntipsychotics in the treatment of schizophrenia: an overviewJ Clin Psychiatry201172Suppl 14822217436
   PubMed Web of Science ®Google Scholar
• MargoleseHCChouinardGKolivakisTTBeauclairLMillerRAnnableLTardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophreniaCan J Psychiatry2005501170371416363464
   PubMed Web of Science ®Google Scholar
• MillerDDCaroffSNDavisSMClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsExtrapyramidal side-effects of antipsychotics in a randomised trialBr J Psychiatry2008193427928818827289
   PubMed Web of Science ®Google Scholar
• PelusoMJLewisSWBarnesTRJonesPBExtrapyramidal motor side-effects of first- and second-generation antipsychotic drugsBr J Psychiatry2012200538739222442101
   PubMed Web of Science ®Google Scholar
• KaneJMKimEKanHJGuoZBatesJAWhiteheadRPikalovAComparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trialsAppl Health Econ Health Policy20097210911919731968
   PubMedGoogle Scholar
• HugenholtzGWHeerdinkERStolkerJJMeijerWEEgbertsACNolenWAHaloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended dosesJ Clin Psychiatry200667689790316848649
   PubMed Web of Science ®Google Scholar
• TardyMDoldMEngelRRLeuchtSFlupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaCochrane Database Syst Rev Epub201491
   Web of Science ®Google Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
   PubMed Web of Science ®Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• ChaudhryIBMinhasMRahmanRWhich antipsychotics would mental health professionals from a low income country choose for themselves?Journal of Pakistan Psychiatric Society2011827983
   Google Scholar
• VerdouxHTournierMBégaudBAntipsychotic prescribing trends: a review of pharmaco-epidemiological studiesActa Psychiatr Scand2010121141020059452
   PubMed Web of Science ®Google Scholar
• NaberDLambertMThe CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansCNS Drugs200923864965919594194
   PubMed Web of Science ®Google Scholar
• KraemerHCGlickIDKleinDFClinical trials design lessons from the CATIE studyAm J Psychiatry2009166111222122819797435
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSSecond-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisonsSchizophr Bull201238116717720513652
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• SangerTMLiebermanJATohenMGrundySBeasleyCTollefsonGDOlanzapine versus haloperidol treatment in first-episode psychosisAm J Psychiatry1999156179879892301
   PubMed Web of Science ®Google Scholar
• HaddadPMDasAKeyhaniSChaudhryIBAntipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisonsJ Psychopharmacol2012265 Suppl152622057019
   PubMed Web of Science ®Google Scholar
• FrackiewiczEJSramekJJHerreraJMKurtzNMCutlerNREthnicity and antipsychotic responseAnn Pharmacother19973111136013699391692
   PubMed Web of Science ®Google Scholar
• StricklandTLSteinRLinKMRisbyEFongRThe pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitionerArch Fam Med1997643713759225711
   PubMedGoogle Scholar
• ChaudhryINeelamKDudduVHusainNEthnicity and psychopharmacologyJ Psychopharmacol200822667368018308818
   PubMed Web of Science ®Google Scholar
• ChaudhryIBHallakJHusainNMinocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatmentJ Psychopharmacol20122691185119322526685
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyWashington, DCU.S. Department of Health, Education and Welfare1976534537
   Google Scholar
• SchoolerNRKaneJMResearch diagnoses for tardive dyskinesiaArch Gen Psychiatry19823944864876121550
   PubMed Web of Science ®Google Scholar
• Joint Formulary CommitteeBritish National Formulary (BNF)London, UKPharmaceutical Press2013
   Google Scholar
• LingjaerdeOAhlforsUGBechPDenckerSJElgenKThe UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patientsActa Psychiatr Scand Suppl198733411002887090
   PubMedGoogle Scholar
• CaroffSNDavisVGMillerDDTreatment Outcomes of Patients With Tardive Dyskinesia and Chronic SchizophreniaJ Clin Psychiatry201172310
   Web of Science ®Google Scholar
• MathewsMGratzSAdetunjiBGeorgeVMathewsMBasilBAntipsychotic-induced movement disordersPsychiatry (Edgmont)2005233641
   Google Scholar
• NovickDHaroJMBertschJHaddadPMIncidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes studyJ Clin Psychopharmacol201030553154020814320
   PubMed Web of Science ®Google Scholar
• HamerSHaddadPMAdverse effects of antipsychotics as outcome measuresBr J Psychiatry Suppl200750s64s7018019047
   PubMedGoogle Scholar
• MorgensternHGlazerWMIdentifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia StudyArch Gen Psychiatry19935097237338102845
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• YassaRNairNPA 10-year follow-up study of tardive dyskinesiaActa Psychiatr Scand19928642622661360742
   PubMed Web of Science ®Google Scholar
• CaroffSNDavisVGMillerDDCATIE InvestigatorsTreatment outcomes of patients with tardive dyskinesia and chronic schizophreniaJ Clin Psychiatry201172329530320816031
   PubMed Web of Science ®Google Scholar
• MarsdenCDJennerPThe pathophysiology of extrapyramidal side-effects of neuroleptic drugsPsychol Med198010155726104342
   PubMed Web of Science ®Google Scholar
• CarlssonABiochemical implications of dopa-induced actions on the central nervous system with particular reference to abnormal movementsBarbeauAMcDowellFHL-DOPA and ParkinsonismPhiladelphia, PADavis1970
   Google Scholar
• KlawansHLRubovitsREffect of cholinergic and anticholinergic agents on tardive dyskinesiaJ Neurol Neurosurg Psychiatry19743789419474418481
   PubMed Web of Science ®Google Scholar
• ChakosMHAlvirJMWoernerMGIncidence and correlates of tardive dyskinesia in first episode of schizophreniaArch Gen Psychiatry19965343133198634009
   PubMed Web of Science ®Google Scholar
• LeeJPoonLYChongSASpontaneous dyskinesia in first-episode psychosis in a Southeast Asian populationJ Clin Psychopharmacol200828553653918794649
   PubMed Web of Science ®Google Scholar
• MorgensternHGlazerWMIdentifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia StudyArch Gen Psychiatry19935097237338102845
   PubMed Web of Science ®Google Scholar
• OosthuizenPPEmsleyRAMaritzJSTurnerJAKeyterNIncidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidolJ Clin Psychiatry20036491075108014628983
   PubMed Web of Science ®Google Scholar
• YassaRJesteDVGender differences in tardive dyskinesia: a critical review of the literatureSchizophr Bull19921847017151359633
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Psychosis and Schizophrenia in Adults: Treatment and Management. Clinical Guideline CG178London, UKNational Institute for Health and Care Excellence2014
   Google Scholar